Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Human (tested or 100% immunogen sequence identity)
Specificity and Use
RBM25 / SNU71 antibody was raised against the epitope recognized by this antibody maps to a region between residue 150 and 200 of human RNA binding motif protein 25 (Arg/Glu/Asp-rich protein, 120 kD) using the numbering given in entry AAF19255.1 (GeneID 58517).
Recognizes human RBM25.
Suitable for use in Western Blot and Immunoprecipitation.
TBS, pH 7.2, 0.1% BSA, 0.1% sodium azide
Long term: Add glycerol (40-50%) -20°C; Short term: +4°C
RBM25 Antibody, NET52 Antibody, Protein S164 Antibody, RNPC7 Antibody, RNA-binding motif protein 25 Antibody, S164 Antibody, Snu71 Antibody, RNA binding motif protein 25 Antibody, FSAP94 Antibody, RED120 Antibody, RNA-binding protein 25 Antibody
RNA-binding protein that acts as a regulator of alternative pre-mRNA splicing. Involved in apoptotic cell death through the regulation of the apoptotic factor BCL2L1 isoform expression. Modulates the ratio of proapoptotic BCL2L1 isoform S to antiapoptotic BCL2L1 isoform L mRNA expression. When overexpressed, stimulates proapoptotic BCL2L1 isoform S 5'-splice site (5'-ss) selection, whereas its depletion caused the accumulation of antiapoptotic BCL2L1 isoform L.